Omeros Shares Plunge After CHMP Rejects Narsoplimab for TA-TMA
Omeros shares fell sharply after the CHMP gave a negative opinion on its drug narsoplimab for transplant-associated thrombotic microangiopathy. Company plans re-examination.
/ 3 items
#OMER↓
FDA Approves First-Ever Treatment for Deadly Stem Cell Transplant Complication
Omeros' (OMER) Yartemlea becomes the first FDA-approved drug for TA-TMA, a life-threatening complication affecting stem cell transplant patients, with launch planned for January 2026.
Omeros Strikes $2.1 Billion Deal, Granting Novo Nordisk Exclusive Global Rights to Zaltenibart
Novo Nordisk acquired the rare disease drug zaltenibart from Omeros for up to $2.1B. It treats disorders like PNH & Novo plans Phase 3.